Can PrEP work for people who use drugs? new study aims to find out

NCT ID NCT07385183

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how to help people who use drugs start and keep taking PrEP, a daily pill that prevents HIV. Researchers will follow 200 participants from the emergency department for one year, tracking who stays on the medication and what helps or hinders them. They will also interview doctors and peer workers to understand barriers. The goal is not to test if PrEP works—that's already proven—but to find real-world solutions for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Descovy (F/TAF)

What this could lead to

If successful, this could show practical ways to improve HIV prevention in a high-risk group that often struggles with access and adherence.

What could go wrong

This is an observational study, not a test of the drug's effectiveness. It may not lead to changes in care if barriers are too complex or if adherence remains low.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREP ADHERENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••